TD Cowen Cuts Bruker (NASDAQ:BRKR) Price Target to $43.00

Bruker (NASDAQ:BRKR) had its price target cut by TD Cowen from $53.00 to $43.00 in a report issued on Friday,Benzinga reports. They currently have a hold rating on the medical research company’s stock.

BRKR has been the topic of a number of other reports. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. The Goldman Sachs Group dropped their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday. Wells Fargo & Company upped their target price on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Guggenheim increased their target price on Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $50.38.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $36.51 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of -243.40, a PEG ratio of 4.78 and a beta of 1.19. The firm’s 50 day simple moving average is $46.92 and its 200-day simple moving average is $40.48. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the company posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker will post 2.69 EPS for the current year.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. The trade was a 5.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parkside Financial Bank & Trust raised its holdings in shares of Bruker by 144.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after acquiring an additional 876 shares during the period. Marshall Wace LLP acquired a new stake in Bruker during the fourth quarter worth about $51,530,000. Inspire Advisors LLC purchased a new position in Bruker during the fourth quarter worth about $305,000. UMB Bank n.a. raised its stake in Bruker by 57.9% during the fourth quarter. UMB Bank n.a. now owns 1,571 shares of the medical research company’s stock worth $74,000 after purchasing an additional 576 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of Bruker by 42.9% in the 4th quarter. First Trust Advisors LP now owns 1,126,866 shares of the medical research company’s stock valued at $53,087,000 after buying an additional 338,217 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q4 revenue beat and conservative upside in full‑year revenue guidance — Bruker reported Q4 revenue of $977.2M, above consensus, and issued FY2026 revenue guidance of about $3.6B (above street revenue consensus), which supports top‑line growth expectations. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Strategic partnership in India to expand spatial biology presence — Bruker partnered with Premas Life Sciences to strengthen tissue research capabilities in India, which could support regional growth and recurring consumable/service revenue. Premas Life Sciences Partners with Bruker Spatial Biology
• Neutral Sentiment: Company released earnings presentation and slide deck — management’s slides and call are available for detail on segments and margin outlook; useful for judging whether revenue guidance is sustainable. Earnings Call Presentation
• Neutral Sentiment: Short‑interest data reported but appears anomalous — filings in mid‑February show zero shares/NaN changes (likely data/reporting noise), so don’t read meaningfully into a short squeeze risk from these entries.
• Negative Sentiment: EPS missed expectations and earnings declined year‑over‑year — Q4 EPS was $0.59 vs. consensus ~$0.65 and vs. $0.76 a year ago, highlighting near‑term margin pressure. Q4 Earnings Miss
• Negative Sentiment: Analysts trimmed forecasts and price targets after the print — multiple analysts lowered estimates and TD Cowen cut its price target from $53 to $43 and moved to a “hold,” which likely pressured the stock. These Analysts Cut Their Forecasts On Bruker TD Cowen note (summary)

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.